Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Etoposide + Indoximod|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 17||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 5||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Indoximod||D-1MT|1-MT|NLG-8189||IDO1 Inhibitor 12||Indoximod (D-1MT) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases metabolism of tryptophan to kynurenine, potentially resulting in increased T-cell proliferation and activation and enhanced anti-tumor immune response (PMID: 17234791, PMID: 32637034, PMID: 34117113).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04049669||Phase II||Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod||Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG||Recruiting||USA||0|